SLC22A7, which was downregulated in HCC yet specifically expressed in malignant cells, has been reported to affect mitochondrion and oxidoreductase in noncancerous liver tissues, thereby promoting the occurrence of HCC (42). Here, SLC22A7 is linked to hepatocellular carcinoma.